SAP, Desert Gold, Novo Nordisk – Strong Rebound Potential

SAP: Potential Rebound on the Horizon

SAP shares are currently under pressure, due in no small part to the company’s rocky AI strategy. Instead of shining through its own technological breakthroughs, the company acts, in the eyes of many critics, merely as an expensive middleman for the major US tech giants. Opaque pricing and growing user concerns about data sovereignty are driving customers away. In practice, the vast majority of companies therefore prefer to rely on external AI tools, while SAP’s internal solutions are barely gaining a foothold in live operations.

To extricate itself from this situation, SAP is now acquiring the US data expert Reltio. This acquisition fuels optimism for a fundamental shift in strategy, with a focus on the previously neglected Business Data Cloud. In the future, Reltio technology is intended to serve as the engine for processing highly fragmented information from a wide variety of third-party systems and seamlessly integrating it into the SAP ecosystem. By creating a flawless, error-free database – the so-called “Clean Core” – SAP’s in-house AI agents will finally be able to deliver reliable analyses.

Although the financial volume of this acquisition is small relative to the market capitalization, the deal is breathing new life into the stock. Analysts view the acquisition as a much-needed operational fresh start and forecast additional momentum for cloud growth. Experts at Bank of America expect revenue growth of up to 12% and are setting price targets of around EUR 258.

From a technical perspective, however, a negative picture is emerging in the short term. The stock has slipped below the psychologically important support zone of EUR 160 and is stuck in an intact downtrend. Due to the technically oversold condition, however, a short and sharp counter-movement is possible, which could extend to closing the price gap at just under EUR 190. For a genuine technical relief, however, highs above the EUR 220 mark would be essential. Fundamentally, a EUR 10 billion share buyback program and stable cash flow are cushioning the current selling pressure.

Desert Gold Ventures – On the Verge of Becoming a Producer

Analysts at GBC AG are optimistic in their latest report on exploration company Desert Gold Ventures, assigning a “Buy” rating with a price target of EUR 0.59 per share by December 31, 2026. The stock is currently trading at EUR 0.08. At the heart of the valuation is a strategic turning point from a traditional explorer to a potential gold producer with foreseeable cash flow. The basis for this is the fully permitted Barani East oxide gold project, which is currently visibly moving from the planning to the implementation phase.
Instead of pure exploration speculation, the focus is shifting to a concrete development and production path, which could permanently change perceptions in the capital market.

Barani East is considered a key value driver and, according to GBC, could be self-sustaining once operational. Revenues of approximately USD 7.35 million are already expected in the first year, which could rise to over USD 33 million during regular operations. At the same time, the project stands out for its capital-disciplined approach. With a modular gravity processing system, Desert Gold is deliberately starting on a small scale to minimize technical risks and quickly demonstrate operational viability. The planned scaling up to higher throughputs opens up additional growth potential with increasing efficiency. The net present value of approximately USD 89.6 million underscores the project’s economic attractiveness and makes Barani East a cornerstone of the overall valuation.

Operationally, development is also gaining momentum. Infrastructure work, site preparations, and technical adjustments are already underway on-site, with commissioning targeted for mid-2026. A recently completed financing round of approximately CAD 7.21 million also secures the next development steps. However, the structural effect is decisive. With the transition to production, Desert Gold could significantly reduce the high exploration risk premium and tap into new investor circles. At the same time, additional upside potential remains due to the extensive project portfolio in Mali and Côte d’Ivoire, resulting in an attractive risk-reward profile.

Novo Nordisk: Medical Triumph, Stock Market Drama

Novo Nordisk is currently experiencing a steep decline. Along with other companies in the industry, the Danish group has recently suffered massive losses in value, reducing its market capitalization by approximately EUR 420 billion. The enormous hype surrounding the weight-loss injection has now faded into the background. Above all, the fierce competition with US rival Eli Lilly is taking a heavy toll on the Danish company. In direct comparison, Novo Nordisk is currently left in the dust. Furthermore, investors are increasingly shunning former growth darlings and reallocating their capital, as geopolitical uncertainties are adding to the pressure on industry alongside internal problems.

Despite the headwinds on the stock market, the company’s core business is sending a strong signal. The US Food and Drug Administration (FDA) recently gave the green light to “Awiqli”. This innovative drug is the world’s first basal insulin for type 2 diabetics that needs to be injected just once a week instead of daily. For patients, this reduction from seven to one injection per week represents an enormous relief in daily life and promises significantly improved treatment adherence. The company is now focusing specifically on maximizing user convenience to successfully differentiate itself from the competition in the diabetes market through particularly patient-friendly innovations.

However, this innovative news is having virtually no impact on the market. Market participants remain concerned about the high competitive pressure. From a technical analysis perspective, the situation is also coming to a head. The stock is trading close to the key support level of EUR 30. If the stock breaks through this level, a rapid decline toward EUR 27 looms, after which even the EUR 20 mark could become a target. Investors currently lack the confidence needed for a sustainable trend reversal.

For SAP, the Reltio deal could lay the groundwork for an operational fresh start despite the weak chart picture and, in the short term, at least trigger a technical rebound. Desert Gold Ventures is facing a potential turning point with Barani East. At Novo Nordisk, despite operational strength, it is becoming clear that without a return of investor confidence, even strong innovations are unlikely to generate much upside potential for the time being.

Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.